Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Trial marks key milestone in driving pipeline progress
Phase 1 trial scheduled for completion mid-June 2025
Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback
HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that the first patient has been dosed in its Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.
The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder and granules when administered orally in healthy adult volunteers. The Phase 1 "crossover" clinical trial, which is being conducted in the United States, will compare the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers administered a sublingual dose of 162.5 mg aspirin powder or granules with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin tablets). The primary outcome measure will be plasma acetylsalicylic acid (ASA) concentration versus time data (pre-dose and up to 24 hours post dose.) This trial will also provide important data about TxB2 and its anti-coagulant bioavailability in the volunteers. For additional information on this trial please visit www.clinicaltrials.gov.
The Company expects to disclose topline data from its high-dose aspirin trial early in the third quarter and if successful, this trial has the potential to support accelerated approval, subject to FDA review.
"Dosing the first patient in our oral transmucosal fast-acting high-dose aspirin formulation study is an important milestone for Aspire as we continue the clinical development of our lead product candidate," said Kraig Higginson, Chief Executive Officer of Aspire. "We are proud that our aspirin formulation is one step closer to our goal of addressing several key unmet needs, and we are grateful to our patients for participating in this trial."
About the Aspire Targeted Oral Delivery Platform
Aspire's technology delivers a soluble, fast acting granular or powder form drug formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technologies new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream. The benefits of "rapid absorption" are to provide nearly instant treatment impact and high dose absorption. The Company's patent-pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract, and potentially provide an improved treatment outcome.
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IRKevin McGrath+1-646-418-7002kevin@tradigitalir.com
SOURCE: Aspire Biopharma Holdings, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 minutes ago
- Associated Press
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal
CNN
23 minutes ago
- CNN
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. Enflonsia is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those things weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.' Correction: A previous version of this story incorrectly described the newly approved monoclonal antibody as a therapy.
Associated Press
25 minutes ago
- Associated Press
TDG Gold Mobilizes Field Team to Greater Shasta-Newberry Copper-Gold Project, Toodoggone
Exploration scheduled to commence in June 2025 with IP followed by Drilling WHITE ROCK, BC / ACCESS Newswire / June 12, 2025 / TDG Gold Corp. (TSXV:TDG)(OTCQX:TDGGF) (the 'Company' or 'TDG') is pleased to announce that its field team has mobilized and will shortly commence TDG's funded 2025 exploration program within the Company's expansive and 100%-owned Greater Shasta-Newberry ('GSN') Project (Figure 1) in the Toodoggone District of British Columbia (Figure 2). Field activities will start with a combination of: (i) soil and rock geochemistry, (ii) Induced Polarisation ('IP') geophysics, (iii) Time-domain electromagnetic geophysics, (iv) ground based magnetic geophysics and, (v) detailed geological mapping (Figure 3), followed by drilling, with the objective of defining copper +/- gold drill targets. The initial focus will be on the area encompassing the Greater Shasta, Newberry and AuWEST areas and will then expand to cover key parts of the 12 kilometre ('km') structural corridor previously defined by TDG (news release Mar 03, 2025 ). This corridor hosts the Freeport-Amarc AuRORA1 discovery along with TDG's Trident target (news release Mar 07, 2024 ) and East Spur target (news release Mar 03, 2025 ). HQ diamond drilling is expected to commence in mid-July with the first drillhole located less than 10 metres from the GSN-AuRORA1 boundary. A further two drillholes are expected to be drilled from the same pad in close proximity to the mineral tenure boundary and the AuRORA1discovery. Additional pads, drillholes and drill rigs are expected to be deployed based on results from the targeting studies as part of a proposed more extensive drill program at GSN and including additional targets prioritized within the 12 km structural corridor. Steven Kramar, TDG's Vice President Exploration, commented: 'TDG's planned field program this season represents a step change in our focus and coverage as we seek to evaluate and drill test a number of copper +/- gold porphyry opportunities on our side of the boundary of the AuRORA1 discovery, and beyond. Operations will be based out of our Baker camp located ~8 km by road from GSN. We are well-funded, and our camp is fully winterized - hence, we anticipate being able to operate through to the end of October and into November, if warranted.' Figure 1 - GSN-AuRORA1 Vicinity. Figure 2 - Map of the Northern Toodoggone. Figure 3 - 2025 Planned Exploration Activities (Shown with Airborne Reduced-to-Pole Magnetic Data). Qualified Person The technical content of this news release has been reviewed and approved by Steven Kramar, MSc., Vice President, Exploration for TDG, a qualified person as defined by National Instrument 43-101. Notes 1Adjacent Properties: The Company has no interest in, or rights to, any of the adjacent properties mentioned, and exploration results on adjacent properties are not necessarily indicative of mineralization on the Company's properties. Any references to exploration results on adjacent properties are provided for information only and do not imply any certainty of achieving similar results on the Company's properties. 2Mineral Resource Estimate (MRE): All scientific and technical information relating to the TDG's Shasta Project pertaining to the Shasta Mineral Resource Estimate ('Shasta MRE') contained in this news release is derived from the Technical Report dated February 21st, 2025 (with an effective date of December 29, 2024) titled '2025 Updated Resource Estimate For The Shasta Deposit' (the '2025 Technical Report') prepared by Sue Bird, MSc., of Moose Mountain Technical Services. The information contained herein in respect of the Shasta MRE is subject to all of the assumptions, qualifications and procedures set out in the 2025 Technical Report and reference should be made to the full text of the 2025 Technical Report, a copy of which has been filed with the securities regulators in each of the provinces of Canada (except Québec) and is available on About TDG Gold Corp. TDG is a major mineral tenure holder in the Toodoggone District of north-central British Columbia, Canada, with 100% ownership of ~50,000 hectares of brownfield and greenfield exploration ground. In 2023, TDG defined the 5.5 Greater Shasta-Newberry exploration target area (news release Jan 25, 2023 ) which is located directly adjacent to the gold-rich copper porphyry AuRORA1 discovery announced by Freeport McMoran Inc. and Amarc Resources Ltd. (news release Jan 17, 2025 ). In 2024, TDG identified new copper-gold target areas over an expanded footprint covering ~53 known as the 'Baker Complex' (news release Feb 28, 2024 ), including the North Quartz (news release Apr 02, 2024 ) and Trident (news release Mar 07, 2024 ) targets. In January 2025, TDG identified an additional porphyry copper +/- molybdenum target at Erebus located within TDG's Bot project (news release Jan 17, 2025 ). In February 2025, TDG completed the Sofia acquisition, which includes porphyry copper +/- molybdenum +/- gold targets ( ARIS Report 41231 ). TDG's other projects within the property package include the former producing, gold-silver Shasta and gold-silver-copper Baker mines, which produced intermittently between 1981-2012, and the historical high-grade gold Mets developed prospect, all of which are road accessible, and combined have over 65,000 m of historical drilling. These projects have been advanced through compilation of historical data, new geological mapping, geochemical and geophysical surveys and, at Shasta, 13,250 m of modern HQ drill testing of the known mineralization occurrences and their potential extensions. In 2025, TDG published an updated Mineral Resource Estimate2 for Shasta (news release Jan 08, 2025 ), which remains open at depth and along strike. ON BEHALF OF THE BOARD Fletcher Morgan Chief Executive Officer For further information contact: TDG Gold Corp. Telephone: +1.604.536.2711 Email: [email protected] Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as 'expansive', 'represent', 'expect', 'opportunity', 'evaluate', 'anticipate', 'extensive' 'objective', , and variations of these words as well as other similar words or statements that certain events or conditions 'could', 'may', 'would' or 'will' occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such factors include, among others: the uncertainty that any mineralization encountered on adjacent properties continues on to TDG tenure; the uncertainty that geological and/or geophysical and/or geochemical anomalies and/or any trends, interpretations, or conclusions based on adjacent properties have relevance to TDG's tenure; whether geophysical anomalies and targets located on TDG's properties represent epithermal and/or porphyry-style mineralization and, if so, whether such mineralization has economic potential; the actual results of current and planned exploration activities; the actual timing of current and planned exploration activities; the interpretation that the Greater Shasta-Newberry Target Area represents a larger mineralized system encompassing several target zones and the potential that such zones may represent additional mineralized target zones; the interpretation that the 12 km structural corridor represents a larger mineralized system encompassing several target zones and the potential that such zones may represent additional mineralized target zones changes in project parameters as plans to continue to be refined; accidents, labour disputes and other risks of the mining industry; the availability of sufficient funding on terms acceptable to the company to complete the planned work programs; delays in obtaining governmental approvals or financing; and fluctuations in metal prices. There may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. SOURCE: TDG Gold Corp. press release
